Global trends and mechanistic insights into A20 (TNFAIP3) in autoimmunity and inflammation

As a pivotal checkpoint in immune homeostasis, the ubiquitin-editing enzyme A20 (encoded by TNFAIP3) exerts profound control over inflammatory cascades. Beyond its established roles in autoimmunity and malignancy, A20 has recently emerged as a critical determinant of therapeutic outcomes. Despite a wealth of bench-to-bedside mechanistic data, a high-level synthesis of how this research landscape has evolved over the past two decades remains elusive. To bridge this gap, we conducted a comprehensive bibliometric mapping of 3,926 English-language publications indexed in the Web of Science Core Collection from 2003 to 2025. By integrating VOSviewer, CiteSpace, and Microsoft Excel, we dissected the intellectual architecture of the field, ranging from institutional collaborative networks to shifts in keyword co-occurrence. Our analysis reveals a robust, multi-phase expansion of the A20 knowledge base, with annual outputs peaking at over 350 papers in 2025. This momentum is largely propelled by a Sino-American research axis, with core clusters identified at University of California, San Francisco (UCSF), Ghent University, and the Chinese Academy of Sciences. We further highlight the seminal influence of investigators like Geert van Loo and Ingrid E. Wertz, whose work has redefined A20's multifaceted roles in NF-κB signaling and regulated cell death. Collectively, this study delineates the maturation of A20 from a simple negative regulator to a context-dependent therapeutic target, offering a strategic roadmap for future translational and disease-specific investigations.